LIC MF Midcap Fund
The scheme seeks to provide investors with the opportunities for long-term capital appreciation by investing predominantly in Equity and Equity related instruments of Midcap Companies.
Growthvine rating: 2/5 — ranked #27 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹30.76 (as of 2026-11-13) |
|---|
| AUM | ₹369 Cr |
|---|
| Expense ratio | 2.10% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Sudhanshu Asthana |
|---|
| Exit load | For units in excess of 12% of the investment, 1% will be charged for redemption within 12 months |
|---|
Performance & risk
| Sharpe ratio | 0.42 |
|---|
| Standard deviation | 19.70% |
|---|
| Max drawdown | −21.92% |
|---|
| Alpha | -0.94 |
|---|
| Beta | 1.04 |
|---|
Over 5 years, captured 98.1% of NIFTY Midcap 150's upside and 102.5% of its downside.
Market cap allocation
| Large cap | 2.8% |
|---|
| Mid cap | 83.4% |
|---|
| Small cap | 13.9% |
|---|
Concentration
| Top 5 holdings | 19.9% |
|---|
| Top 10 holdings | 35.9% |
|---|
| Total holdings | 35 |
|---|
| Index overlap | 29.4% |
|---|
| Active share | 70.6% |
|---|
Top holdings
- AU Small Finance Bank Limited — 4.3%
- Aditya Birla Capital Ltd — 4.1%
- FSN E-Commerce Ventures Limited — 4.1%
- Aurobindo Pharma Ltd. — 3.9%
- JSW Infrastructure Limited — 3.5%
- COFORGE LIMITED — 3.4%
- Persistent Systems Limited — 3.3%
- Aster DM Healthcare Limited — 3.2%
- Neuland Laboratories Limited. — 3.2%
- Godrej Properties Limited — 3.0%
Top sectors
- Banking & Financial — 17.0%
- Retail — 9.8%
- Pharma & Biotech — 9.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 5.3% | Q3 | #17 of 31 |
| 2025 | −1.2% | Q4 (Bottom) | #24 of 29 |
| 2024 | 29.1% | Q2 | #14 of 29 |